Last reviewed · How we verify

Delamanid in Oral Dosage Form

Wits Health Consortium (Pty) Ltd · Phase 3 active Small molecule

Delamanid in Oral Dosage Form is a Mycobacterial cell wall synthesis inhibitor Small molecule drug developed by Wits Health Consortium (Pty) Ltd. It is currently in Phase 3 development for Drug-resistant tuberculosis (MDR-TB and XDR-TB), Pulmonary tuberculosis in combination with other anti-tuberculous agents. Also known as: Deltyba.

Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis.

Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis. Used for Drug-resistant tuberculosis (MDR-TB and XDR-TB), Pulmonary tuberculosis in combination with other anti-tuberculous agents.

At a glance

Generic nameDelamanid in Oral Dosage Form
Also known asDeltyba
SponsorWits Health Consortium (Pty) Ltd
Drug classMycobacterial cell wall synthesis inhibitor
TargetDprE1 (decaprenylphosphoryl-arabinose-1-phosphatase)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Delamanid is a nitro-aromatic prodrug that is activated by mycobacterial enzymes to form reactive intermediates that inhibit the enzyme DprE1, which is essential for the synthesis of decaprenylphosphoryl-arabinose—a critical precursor for mycolic acid biosynthesis in the mycobacterial cell wall. By disrupting cell wall integrity, delamanid leads to mycobacterial cell death and is particularly effective against drug-resistant tuberculosis strains.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Delamanid in Oral Dosage Form

What is Delamanid in Oral Dosage Form?

Delamanid in Oral Dosage Form is a Mycobacterial cell wall synthesis inhibitor drug developed by Wits Health Consortium (Pty) Ltd, indicated for Drug-resistant tuberculosis (MDR-TB and XDR-TB), Pulmonary tuberculosis in combination with other anti-tuberculous agents.

How does Delamanid in Oral Dosage Form work?

Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis.

What is Delamanid in Oral Dosage Form used for?

Delamanid in Oral Dosage Form is indicated for Drug-resistant tuberculosis (MDR-TB and XDR-TB), Pulmonary tuberculosis in combination with other anti-tuberculous agents.

Who makes Delamanid in Oral Dosage Form?

Delamanid in Oral Dosage Form is developed by Wits Health Consortium (Pty) Ltd (see full Wits Health Consortium (Pty) Ltd pipeline at /company/wits-health-consortium-pty-ltd).

Is Delamanid in Oral Dosage Form also known as anything else?

Delamanid in Oral Dosage Form is also known as Deltyba.

What drug class is Delamanid in Oral Dosage Form in?

Delamanid in Oral Dosage Form belongs to the Mycobacterial cell wall synthesis inhibitor class. See all Mycobacterial cell wall synthesis inhibitor drugs at /class/mycobacterial-cell-wall-synthesis-inhibitor.

What development phase is Delamanid in Oral Dosage Form in?

Delamanid in Oral Dosage Form is in Phase 3.

What are the side effects of Delamanid in Oral Dosage Form?

Common side effects of Delamanid in Oral Dosage Form include Nausea, Vomiting, Abdominal pain, Headache, Peripheral neuropathy, QT prolongation.

What does Delamanid in Oral Dosage Form target?

Delamanid in Oral Dosage Form targets DprE1 (decaprenylphosphoryl-arabinose-1-phosphatase) and is a Mycobacterial cell wall synthesis inhibitor.

Related